Evidence map›Paper›PMID 32647803›Full record

ArticleHemaSphere2020

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.

Kirill V Lepik, Natalia B Mikhailova, Elena V Kondakova, Yuri R Zalyalov, Liudmila V Fedorova, Luibov A Tsvetkova, Polina V Kotselyabina, Evgeniya S Borzenkova, Elena V Babenko, Marina O Popova and 4 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. [Treatment challenges and optimal management of classical Hodgkin's lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Prognostic role of pretreatmentBMC medical imaging · 2023
    Article
  10. [The guidelines for diagnosis and treatment of Hodgkin lymphoma in China (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Kirill V LepikRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Natalia B MikhailovaRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Elena V KondakovaRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Yuri R ZalyalovRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Liudmila V FedorovaRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Luibov A TsvetkovaRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Polina V KotselyabinaRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Evgeniya S BorzenkovaRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Elena V BabenkoRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Marina O PopovaRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Elena I DarskayaRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Vadim V BaykovRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Ivan S MoiseevRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
Boris V AfanasyevRaisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation.
First Pavlov State Medical University of St. Petersburg · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received nivolumab (3 mg/kg) on D1,14 and bendamustine (90 mg/m

Identifiers

PMID32647803
PMCPMC7306298
OpenAlexW3041892221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.